Drugdiscovery >> Pharmaceutical Companies >> News
4835
Views
title
Agenus shares fall after GSK’s MAGE-A3 failure in a Phase 3 trial - drugdiscovery.com


Glaxo’s MAGE-A3 immunotherapy treatment includes Agenus' SQ-21 Stimulon vaccine adjuvant which is designed to make drugs more effective. GSK reported that MAGE-A3 failed to meet its first goal in a mid-stage clinical trial in advanced melanoma patients.
Read More >>


Tags: Agenus, shares, GSK, melanoma clinical trial, MAGE-A3, SQ-21 Stimulon vaccine adjuvant, vaccine adjuvant - September 8, 2013
Related Articles
5576
Views
Isis shares climbe after positive results from its spinal muscular atrophy drug study Isis shares climbe after positive results from its spinal muscular atrophy drug study
Isis Pharmaceuticals drug designed to treat spinal muscular atrophy showed success in a mid- stage study. This announcement led to a raise of company’s shares. Read More >>

Tags: news, Isis Pharmaceutical, spinal muscular atrophy, clinical trial, shares, experimental drug

3155
Views
Rockwell’s anemia drug successful in a second late-stage clinical trial Rockwell’s anemia drug successful in a second late-stage clinical trial
Rockwell Medical reported successful results of its experimental anemia drug - SFP, or soluble ferric phosphate, in a second late-stage clinical trial. Small, frequent doses of SFP proved to be safer Read More >>

Tags: Rockwell Medical, rockwell, anemia drug, SFP, soluble ferric phosphate, clinical trial, shares

1553
Views
Neumedicines ha a new Phase I study Neumedicines ha a new Phase I study
Neumedicines announced that their proposal to conduct a Phase I clinical study of recombinant human interleukin-12 (rHuIL-12) for the treatment of traumatic wounds has been recommended for funding sub Read More >>

Tags: Neumedicines, phase I study, phase I clinical trial, drugresearch, drug discovery

3241
Views
Catalyst Pharmaceutical shares rise Catalyst Pharmaceutical shares rise
After analyst’s good prognosis for the drug Firdapse, the company’s shares rose. Firdapse is intended to be used as a treatment for a rare autoimmune disease called Lambert-Eaton Myasthenic Syndr Read More >>

Tags: Catalyst Pharmaceutical, shares, Firdapse

3164
Views
Ludwig Institute for Cancer Research and Agenus developing vaccine together Ludwig Institute for Cancer Research and Agenus developing vaccine together
The Ludwig Institute for Cancer Research and Agenus are named heir selection of three monoclonal antibody checkpoint modulators. The research is going to be a part of the companies' cacer vaccine proj Read More >>

Tags: Cancer vaccine, antibody, monoclonal antibody checkpoint modulators, Agenus, Ludwig Institute for Cancer Research

4332
Views
A new leukemia drug id going to be made by Pfizer A new leukemia drug id going to be made by Pfizer
Avalliaon Group and Pfizer work together on developing a new type of pharma. The leukemia drug is in Phase 3 clinical trial now. Read More >>

Tags: Phase , clinical trial, pharma

2063
Views
AstraZeneca suffers 17% fall, but still stands AstraZeneca suffers 17% fall, but still stands
Astra zeneca suffered 17% loss on stock exchange due to patent loosings of veteran drugs. However, the company is still positive about its future and hopes to regain what it has lost. Read More >>

Tags: pharma, pharmaceutical companies, pharma loss, Astra Zeneca, veteran drugs

3799
Views
Sanofi's profilts fall Sanofi's profilts fall
Sanofi hurt by generic competition and Brazil woes Read More >>

Tags: Sanofi, profit

3759
Views
Agenus and Merck collaborate on research towards immune checkpoints Agenus and Merck collaborate on research towards immune checkpoints
Agenus, an immuno-oncology company is going to contribute with Merck on developing therapeutic antibodies for immune checkpoints. This technique will open a new chapter in the field of cancer research Read More >>

Tags: cancer, immune checkpoint, cancer research

4836
Views
AstraZeneca pleased with quarter despite profits fall AstraZeneca pleased with quarter despite profits fall
Patent expiries continue to hurt sales and earnings Read More >>

Tags: AstraZeneca, profits

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013